Poly Medicure Limited
POLYMED · General/Diversified · NSE
₹1,491
Current Market Price
Fair Value (DCF)
₹622
Margin of Safety
-58.3%
Updated just now
YieldIQ Score
50/100
Piotroski F-Score
6/9
Economic Moat
Moderate
Confidence
30%
ROE
12.2%
Debt/Equity
0.00
WACC
12.8%
Market Cap
₹0.15 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
16.4%
Return on capital employed
EV / EBITDA
25.3×
Enterprise multiple
Debt / EBITDA
0.4×
Leverage vs earnings
Interest Coverage
40.5×
EBIT covers interest
Current Ratio
5.18×
Short-term liquidity
Asset Turnover
0.49×
Revenue per ₹ of assets
Revenue CAGR (3Y)
16.8%
3-year revenue growth
Revenue CAGR (5Y)
17.6%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,491
Bear case
₹382.28
MoS -290.0%
Base case
₹622
MoS -139.7%
Bull case
₹772.58
MoS -93.0%
Ratio Trends
POLYMED · last 8 annual periods
ROE
12.2%
ROCE
18.6%
Operating Margin
—
Debt / Equity
0.07×
PE
164.2×
EV / EBITDA
32.2×
Historical Financials
POLYMED · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹786 Cr | ₹917 Cr | ₹1109 Cr | ₹1366 Cr | ₹1655 Cr | +20.4% |
| EBITDA | — | ₹253 Cr | ₹303 Cr | ₹419 Cr | ₹547 Cr | +21.3% |
| EBIT | ₹185 Cr | ₹197 Cr | ₹244 Cr | ₹353 Cr | — | +17.5% |
| PAT | ₹136 Cr | ₹147 Cr | ₹179 Cr | ₹258 Cr | ₹339 Cr | +25.6% |
| EPS (diluted) | ₹15.24 | ₹15.27 | ₹18.67 | ₹26.90 | — | +15.3% |
| CFO | ₹119 Cr | ₹123 Cr | ₹191 Cr | ₹266 Cr | ₹240 Cr | +19.3% |
| CapEx | — | ₹-156 Cr | ₹-239 Cr | ₹-277 Cr | ₹-331 Cr | — |
| FCF | — | ₹-32.1 Cr | ₹-48.2 Cr | ₹-10.9 Cr | ₹-90.6 Cr | — |
| Total Assets | — | ₹1377 Cr | ₹1577 Cr | ₹1859 Cr | ₹3192 Cr | +23.4% |
| Total Debt | — | ₹127 Cr | ₹149 Cr | ₹174 Cr | ₹180 Cr | +9.2% |
| Shareholders' Equity | — | ₹1087 Cr | ₹1242 Cr | ₹1470 Cr | ₹2766 Cr | +26.3% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
POLYMED vs 1 closest peer by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| AGARWALEYE AGARWALEYE | — | — | Pending | 4.5% | — |
Click a ticker to view its fair-value analysis.
Dividend History
12 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹14.50/sh
Last payout
2025-09-18
₹3.50
Peak payout
₹3.50
Trailing yield
0.23%
Amounts parsed from NSE subject lines; percent-of-face-value declarations are not converted and shown as missing.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of POLYMED →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for POLYMED →
Compare
Head-to-head with peers
Compare POLYMED side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse POLYMEDNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.